Andrew Strong

Andrew Strong

Hogan Lovells

Contact
View Bio
RSS

Latest Posts › Food and Drug Administration (FDA)

Share:

JPM2024: Manufacturing outlook for transformative technologies

Cell, tissue, and gene therapies (CTGT) have for years offered the potential for truly personalized medicine for many near-incurable disease indications. In addition, radiopharmaceuticals and custom medical device...more

1/4/2024  /  Food and Drug Administration (FDA) , Life Sciences , Manufacturers , Medical Devices , Pharmaceutical Industry , Supply Chain

Getting START’ed: New FDA programs aim to advance drugs to treat rare diseases

On September 29, 2023, the U.S. Food and Drug Administration (FDA or "agency") announced the opportunity for a limited number of sponsors to participate in a new pilot program called Support for clinical Trials Advancing Rare...more

10/12/2023  /  Biologics , Center for Biologics Evaluation and Research (CBER) , Center for Drug Evaluation and Research (CDER) , Food and Drug Administration (FDA) , Life Sciences , Pharmaceutical Industry , Prescription Drugs

JPM2023 Trendspotting: takeaways from Biotech Showcase

At the recent J.P. Morgan Healthcare Conference (JPM) and Biotech Showcase in San Francisco, our market-leading life sciences and health care industry led in-person discussions with industry experts on topics that will guide...more

2/3/2023  /  Biologics , Biosimilars , Biotechnology , Drug Pricing , FDA Approval , Food and Drug Administration (FDA) , Inflation Reduction Act (IRA) , Life Sciences , Pharmaceutical Industry
3 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide